Screener
Royalty Pharma RPRX Non-Controlling Interests
Non-Controlling Interests at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Class R redeemable shares, £1 par value; issued and outstanding: 2026–50 and 2025–50 | 63 | 63 |
| Deferred shares, $0.000001 par value; issued and outstanding: 2026–430,189 and 2025–411,475 | — | — |
| Additional paid-in capital | 4,376,266 | 4,123,088 |
| Retained earnings | 2,459,089 | 2,356,318 |
| Non-controlling interests | 2,952,975 | 3,238,039 |
| Treasury interests | (2,724) | (2,612) |
| Total shareholders’ equity | 9,785,714 | 9,714,939 |
| Total liabilities and shareholders’ equity | $19,819,771 | $19,620,780 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's non-controlling interests?
- Royalty Pharma (RPRX) reported non-controlling interests of $2.95B in Q2 2026.
- How has Royalty Pharma's non-controlling interests changed year-over-year?
- Royalty Pharma's non-controlling interests decreased by 6.4% year-over-year, from $3.16B to $2.95B.
- What is the long-term trend for Royalty Pharma's non-controlling interests?
- Over 5 years (2020 to 2025), Royalty Pharma's non-controlling interests has grown at a -8.6% compound annual growth rate (CAGR), from $5.08B to $3.24B.
- What does non-controlling interests mean?
- Equity attributable to minority shareholders in subsidiaries not fully owned by the parent — their proportional claim on subsidiary net assets.
Ask your AI about Royalty Pharma's non-controlling interests.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude